These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14978453)

  • 1. Beyond control of acute exacerbation: enhancing affective and cognitive outcomes.
    Meltzer HY
    CNS Spectr; 2003 Nov; 8(11 Suppl 2):16-8, 22. PubMed ID: 14978453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
    Meltzer HY; McGurk SR
    Schizophr Bull; 1999; 25(2):233-55. PubMed ID: 10416729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.
    Rossi A; Mancini F; Stratta P; Mattei P; Gismondi R; Pozzi F; Casacchia M
    Acta Psychiatr Scand; 1997 Jan; 95(1):40-3. PubMed ID: 9051159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clozapine on cognitive function in schizophrenia.
    Lee MA; Thompson PA; Meltzer HY
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
    Saavedra-Velez C; Yusim A; Anbarasan D; Lindenmayer JP
    J Clin Psychiatry; 2009 Jan; 70(1):104-12. PubMed ID: 19026265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cognition in the risk--benefit and safety analysis of antipsychotic medication.
    Borison RL
    Acta Psychiatr Scand Suppl; 1996; 389():5-11. PubMed ID: 8985471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E; Lussier I
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs.
    Ichikawa J; Meltzer HY
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 4():90-8. PubMed ID: 10654114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food and Drug Administration commentary on methodological issues in negative symptom trials.
    Laughren T; Levin R
    Schizophr Bull; 2011 Mar; 37(2):255-6. PubMed ID: 21245124
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment-resistant schizophrenia--the role of clozapine.
    Meltzer HY
    Curr Med Res Opin; 1997; 14(1):1-20. PubMed ID: 9524789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone and cognition: the evolving story.
    Harvey PD
    J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.
    Harvey PD; Patterson TL; Potter LS; Zhong K; Brecher M
    Am J Psychiatry; 2006 Nov; 163(11):1918-25. PubMed ID: 17074943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.
    Molina V; Taboada D; Aragüés M; Hernández JA; Sanz-Fuentenebro J
    Schizophr Res; 2014 Sep; 158(1-3):223-9. PubMed ID: 25088730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
    Cuesta MJ; Peralta V; Zarzuela A
    Schizophr Res; 2001 Mar; 48(1):17-28. PubMed ID: 11278151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?
    Weiser M; Shneider-Beeri M; Nakash N; Brill N; Bawnik O; Reiss S; Hocherman S; Davidson M
    Schizophr Res; 2000 Dec; 46(2-3):81-9. PubMed ID: 11120419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.